WO2003102131A3 - Nucleic acid mediated disruption of hiv fusogenic peptide interactions - Google Patents
Nucleic acid mediated disruption of hiv fusogenic peptide interactions Download PDFInfo
- Publication number
- WO2003102131A3 WO2003102131A3 PCT/US2003/012626 US0312626W WO03102131A3 WO 2003102131 A3 WO2003102131 A3 WO 2003102131A3 US 0312626 W US0312626 W US 0312626W WO 03102131 A3 WO03102131 A3 WO 03102131A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hiv
- nucleic acid
- fusogenic peptide
- acid mediated
- peptide interactions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/332—Abasic residue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003228667A AU2003228667A1 (en) | 2002-04-22 | 2003-04-22 | Nucleic acid mediated disruption of hiv fusogenic peptide interactions |
US10/892,922 US20050124569A1 (en) | 2001-05-18 | 2004-07-16 | RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA) |
US10/923,473 US20050191618A1 (en) | 2001-05-18 | 2004-08-20 | RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA) |
US12/334,181 US20090264504A1 (en) | 2001-05-18 | 2008-12-12 | RNA INTERFERENCE MEDIATED INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US12/777,767 US8008472B2 (en) | 2001-05-29 | 2010-05-11 | RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA) |
Applications Claiming Priority (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37472202P | 2002-04-22 | 2002-04-22 | |
US60/374,722 | 2002-04-23 | ||
US10/157,580 | 2002-05-29 | ||
US10/157,580 US20030124513A1 (en) | 2001-05-29 | 2002-05-29 | Enzymatic nucleic acid treatment of diseases or conditions related to levels of HIV |
US38678202P | 2002-06-06 | 2002-06-06 | |
US60/386,782 | 2002-06-06 | ||
US39803602P | 2002-07-23 | 2002-07-23 | |
US60/398,036 | 2002-07-23 | ||
US10/225,023 US20030175950A1 (en) | 2001-05-29 | 2002-08-21 | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
US10/225,023 | 2002-08-21 | ||
US40678402P | 2002-08-29 | 2002-08-29 | |
US60/406,784 | 2002-08-29 | ||
US40837802P | 2002-09-05 | 2002-09-05 | |
US60/408,378 | 2002-09-05 | ||
US40929302P | 2002-09-09 | 2002-09-09 | |
US60/409,293 | 2002-09-09 | ||
US44012903P | 2003-01-15 | 2003-01-15 | |
US60/440,129 | 2003-01-15 | ||
PCT/US2003/005190 WO2003070193A2 (en) | 2002-02-20 | 2003-02-20 | RNA INTERFERENCE MEDIATED INHIBITION OF HIV GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
USPCT/US03/05190 | 2003-02-20 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/420,194 Continuation-In-Part US20040006035A1 (en) | 2001-05-18 | 2003-04-22 | Nucleic acid mediated disruption of HIV fusogenic peptide interactions |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/892,922 Continuation-In-Part US20050124569A1 (en) | 2001-05-18 | 2004-07-16 | RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA) |
US10/923,473 Continuation-In-Part US20050191618A1 (en) | 2001-05-18 | 2004-08-20 | RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA) |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003102131A2 WO2003102131A2 (en) | 2003-12-11 |
WO2003102131A3 true WO2003102131A3 (en) | 2004-04-01 |
Family
ID=32046225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/012626 WO2003102131A2 (en) | 2001-05-18 | 2003-04-22 | Nucleic acid mediated disruption of hiv fusogenic peptide interactions |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003228667A1 (en) |
WO (1) | WO2003102131A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8957198B2 (en) | 2003-02-03 | 2015-02-17 | Medtronic, Inc. | Compositions, devices and methods for treatment of Huntington's disease through intracranial delivery of sirna |
US9133517B2 (en) | 2005-06-28 | 2015-09-15 | Medtronics, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
US9273356B2 (en) | 2006-05-24 | 2016-03-01 | Medtronic, Inc. | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
US9375440B2 (en) | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0226374D0 (en) * | 2002-11-12 | 2002-12-18 | Isis Innovation | Ligands |
US7618948B2 (en) | 2002-11-26 | 2009-11-17 | Medtronic, Inc. | Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA |
EP1993584B1 (en) * | 2006-02-02 | 2012-05-30 | Allergan, Inc. | Inhibitors of CXCR4 activity for use in the treatment of ocular disorders |
CA2812962C (en) | 2010-09-22 | 2020-03-31 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
CN106086075B (en) * | 2016-06-23 | 2019-08-06 | 福建医科大学 | The construction method of CXCR4RNAi slow virus carrier |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994001550A1 (en) * | 1992-07-02 | 1994-01-20 | Hybridon, Inc. | Self-stabilized oligonucleotides as therapeutic agents |
WO2000001846A2 (en) * | 1998-07-03 | 2000-01-13 | Devgen N.V. | Characterisation of gene function using double stranded rna inhibition |
CA2359180A1 (en) * | 1999-01-30 | 2000-08-03 | Roland Kreutzer | Method and medicament for inhibiting the expression of a given gene |
-
2003
- 2003-04-22 WO PCT/US2003/012626 patent/WO2003102131A2/en not_active Application Discontinuation
- 2003-04-22 AU AU2003228667A patent/AU2003228667A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994001550A1 (en) * | 1992-07-02 | 1994-01-20 | Hybridon, Inc. | Self-stabilized oligonucleotides as therapeutic agents |
WO2000001846A2 (en) * | 1998-07-03 | 2000-01-13 | Devgen N.V. | Characterisation of gene function using double stranded rna inhibition |
CA2359180A1 (en) * | 1999-01-30 | 2000-08-03 | Roland Kreutzer | Method and medicament for inhibiting the expression of a given gene |
Non-Patent Citations (2)
Title |
---|
PARK ET AL.: "Specific inhibition of HIV-1 gene expression by double-stranded RNA", NUCLEIC ACIDS RESEARCH SUPPLEMENT, no. 1, pages 219 - 220, XP002972441 * |
STARCICH ET AL.: "Characterization of long terminal repeat sequences of HTLV-III", SCIENCE, vol. 227, no. 4686, January 1985 (1985-01-01), pages 538 - 540, XP002972440 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8957198B2 (en) | 2003-02-03 | 2015-02-17 | Medtronic, Inc. | Compositions, devices and methods for treatment of Huntington's disease through intracranial delivery of sirna |
US9133517B2 (en) | 2005-06-28 | 2015-09-15 | Medtronics, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
US9273356B2 (en) | 2006-05-24 | 2016-03-01 | Medtronic, Inc. | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
US9375440B2 (en) | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
Also Published As
Publication number | Publication date |
---|---|
WO2003102131A2 (en) | 2003-12-11 |
AU2003228667A1 (en) | 2003-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017374044B2 (en) | Modified guide RNAs | |
AU2015355546B2 (en) | Guide RNA with chemical modifications | |
US20170088828A1 (en) | Compositions and methods for treatment of latent viral infections | |
Jacquenet et al. | Conserved stem–loop structures in the HIV-1 RNA region containing the A3 3′ splice site and its cis-regulatory element: possible involvement in RNA splicing | |
WO2003102131A3 (en) | Nucleic acid mediated disruption of hiv fusogenic peptide interactions | |
WO2007130073A3 (en) | Novel reagents for transfection of eukaryotic cells | |
JP2023552374A (en) | Operated class 2 V-type CRISPR system | |
Mougel et al. | Conformational analysis of the 5'leader and the gag initiation site of Mo-MuLV RNA and allosteric transitions induced by dimerization | |
CA3116331A1 (en) | Compositions and methods for expressing factor ix | |
BRPI0714495B8 (en) | Deficient lentivirus for pseudotyped recombinant replication | |
Haines et al. | Chinese hamster ovary cell lines selected for resistance to ebolavirus glycoprotein mediated infection are defective for NPC1 expression | |
Elmén et al. | Locked nucleic acid containing antisense oligonucleotides enhance inhibition of HIV-1 genome dimerization and inhibit virus replication | |
Kameoka et al. | The Tat protein of human immunodeficiency virus type 1 (HIV-1) can promote placement of tRNA primer onto viral RNA and suppress later DNA polymerization in HIV-1 reverse transcription | |
US20090305281A1 (en) | Novel inhibitors of retroviral reverse transcriptace | |
Lainé et al. | In vitro and in vivo cleavage of HIV-1 RNA by new SOFA-HDV ribozymes and their potential to inhibit viral replication | |
Wilhelm et al. | CTGC motifs within the HIV core promoter specify Tat-responsive pre-initiation complexes | |
Wu et al. | Functional coupling between a distal interaction and the cleavage site in bacterial RNase-P-RNA-mediated cleavage | |
JP2023508400A (en) | Targeted integration into mammalian sequences to enhance gene expression | |
WO2012159120A3 (en) | Gene therapy based strategy for treating hiv | |
Escors et al. | Lentiviral vectors and gene therapy | |
WO2022170194A2 (en) | Lymphocyte activation gene 3 (lag3) compositions and methods for immunotherapy | |
EP4288089A2 (en) | T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy | |
MX2022002060A (en) | A prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells. | |
Wilson et al. | A mechanistic comparison of the Varkud satellite and hairpin ribozymes | |
Barroso-delJesus et al. | Inhibition of HIV-1 replication by an improved hairpin ribozyme that includes an RNA decoy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |